WO2004039307A3 - Methods and compositions for diagnosing and treating companion animal cancer - Google Patents

Methods and compositions for diagnosing and treating companion animal cancer Download PDF

Info

Publication number
WO2004039307A3
WO2004039307A3 PCT/IB2003/004635 IB0304635W WO2004039307A3 WO 2004039307 A3 WO2004039307 A3 WO 2004039307A3 IB 0304635 W IB0304635 W IB 0304635W WO 2004039307 A3 WO2004039307 A3 WO 2004039307A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
trail
apoptosis
related disorders
cancer
Prior art date
Application number
PCT/IB2003/004635
Other languages
French (fr)
Other versions
WO2004039307A2 (en
Inventor
Jenny Hong Cai
Sing Rong
Original Assignee
Pfizer Prod Inc
Jenny Hong Cai
Sing Rong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Jenny Hong Cai, Sing Rong filed Critical Pfizer Prod Inc
Priority to AU2003269378A priority Critical patent/AU2003269378A1/en
Priority to JP2004547882A priority patent/JP2006506985A/en
Priority to EP03751159A priority patent/EP1558631A4/en
Publication of WO2004039307A2 publication Critical patent/WO2004039307A2/en
Publication of WO2004039307A3 publication Critical patent/WO2004039307A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The present invention relates to polynucleotides associated with apoptosis-related disorders. The present invention also relates to canine and feline TRAIL genes, novel genes associated with apoptosis-related disorders, such as cancer. The invention encompasses TRAIL nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof, TRAIL gene products and antibodies directed against such gene products, cloning vectors containing mammalian TRAIL gene molecules, and hosts that have been genetically engineered to express such molecules. The invention further relates to methods for the identification of compounds that modulate the expression of TRAIL genes and gene products and to the use of such compounds as therapeutic agents in the treatment of apoptosis-related disorders, e.g., cancer. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of apoptosis-related disorders, e.g., cancer, and to methods and compositions for the treatment these disorders.
PCT/IB2003/004635 2002-10-30 2003-10-21 Methods and compositions for diagnosing and treating companion animal cancer WO2004039307A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003269378A AU2003269378A1 (en) 2002-10-30 2003-10-21 Methods and compositions for diagnosing and treating companion animal cancer
JP2004547882A JP2006506985A (en) 2002-10-30 2003-10-21 Methods and compositions for diagnosing and treating cancer of companion animals
EP03751159A EP1558631A4 (en) 2002-10-30 2003-10-21 Methods and compositions for diagnosing and treating companion animal cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42234202P 2002-10-30 2002-10-30
US60/422,342 2002-10-30

Publications (2)

Publication Number Publication Date
WO2004039307A2 WO2004039307A2 (en) 2004-05-13
WO2004039307A3 true WO2004039307A3 (en) 2005-04-14

Family

ID=32230341

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/004635 WO2004039307A2 (en) 2002-10-30 2003-10-21 Methods and compositions for diagnosing and treating companion animal cancer

Country Status (5)

Country Link
US (1) US20040146896A1 (en)
EP (1) EP1558631A4 (en)
JP (1) JP2006506985A (en)
AU (1) AU2003269378A1 (en)
WO (1) WO2004039307A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294483B2 (en) * 2004-03-11 2007-11-13 Genentech, Inc. Process for producing recombinant polypeptides via a glycerol phosphate or sugar phosphate feed
WO2008088582A2 (en) * 2006-08-04 2008-07-24 Mayo Foundation For Medical Education And Research Methods and materials related to trail isoforms
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
CN108601819B (en) 2015-12-17 2022-03-15 约翰霍普金斯大学 Amelioration of systemic sclerosis with death receptor agonists
JP7281795B2 (en) 2016-04-07 2023-05-26 ザ・ジョンズ・ホプキンス・ユニバーシティー Compositions and methods for treating pancreatitis and pain with death receptor agonists
KR20220048964A (en) * 2020-10-13 2022-04-20 신동준 A recombinant protein with anticancer for dogs and composition for treating cancer of dogs comprising the recombinant protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ASHKENZAI A. ET AL.: "Death receptors: signaling and modulation", SCIENCE, vol. 281, 28 August 1998 (1998-08-28), pages 1305 - 1308 *

Also Published As

Publication number Publication date
US20040146896A1 (en) 2004-07-29
EP1558631A2 (en) 2005-08-03
AU2003269378A8 (en) 2004-05-25
EP1558631A4 (en) 2006-10-04
JP2006506985A (en) 2006-03-02
WO2004039307A2 (en) 2004-05-13
AU2003269378A1 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
WO2004053079A3 (en) Compositions, splice variants and methods relating to ovarian specific genes and proteins
WO2002092764A3 (en) Transgenic animal model of bone mass modulation
MXPA03010077A (en) Transgenic animal model of bone mass modulation.
EP1197550A3 (en) Methods and compositions for diagnosing and treating disorders involving angiogenesis
WO2002086071A3 (en) Cancer-testis antigens
WO2004039307A3 (en) Methods and compositions for diagnosing and treating companion animal cancer
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
EP1284297A3 (en) Identification and use of molecules implicated in pain
NO20021146D0 (en) Polymorphisms in the human CYP3A4 and CYP3A7 genes and their use in diagnostic and therapeutic applications
EP1191036A3 (en) Methods and compositions for diagnosing and treating disorders involving angiogenesis
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO1999004825A8 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
WO2004050860A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO1999031260A3 (en) Regulatory sequences involved in pancreas-specific gene expression
WO2004013311A3 (en) Compositions and methods relating to ovarian specific genes and proteins
WO2005017102A3 (en) Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
WO2001076457A3 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2004042363A3 (en) In vivo imaging of e2f-regulated bioluminescent proteins
WO2004050858A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO2001034772A3 (en) METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME 18q RELATED DISORDERS
WO2003066877A3 (en) Compositions and methods relating to hepatic specific genes and proteins
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2001034771A3 (en) METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME 18q RELATED DISORDERS
WO2005054426A3 (en) Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof
WO2003087408A3 (en) Schizophrenia associated genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003751159

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004547882

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003751159

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2003751159

Country of ref document: EP